Association Between Serum Lipids and Survival in Patients With Amyotrophic Lateral Sclerosis: A Meta-analysis and Population-Based Study.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
07 03 2023
07 03 2023
Historique:
received:
03
03
2022
accepted:
20
10
2022
pubmed:
3
12
2022
medline:
9
3
2023
entrez:
2
12
2022
Statut:
ppublish
Résumé
To explore the association between lipids, polygenic profile scores (PPS) for biomarkers of lipid metabolism, markers of disease severity, and survival in patients with amyotrophic lateral sclerosis (ALS). We meta-analyzed the current literature on the prognostic value of lipids in patients with ALS. Subsequently, we evaluated the relationship between lipid levels at diagnosis, clinical disease stage, and survival in all consecutive patients diagnosed in the Netherlands. We determined the hazard ratio (HR) of each lipid for overall survival, defined as death from any cause. A subset of patients was matched to a previous genome-wide association study; data were used to calculate PPS for biomarkers of lipid metabolism and to determine the association between observed lipid levels at diagnosis and survival. Meta-analysis of 4 studies indicated that none of the biomarkers of the lipid metabolism were statistically significantly associated with overall survival; there was, however, considerable heterogeneity between study results. Using individual patient data (N = 1,324), we found that increased high-density lipoprotein (HDL) cholesterol was associated with poorer survival (HR of 1.33 (95% CI 1.14-1.55, Lipids may contain valuable information about disease severity and prognosis, but their main value may be driven as a consequence of disease progression. Our results underscore that gaining further insight into lipid metabolism and longitudinal data on serum concentrations of the lipid profile could improve the monitoring of patients and potentially further disentangle ALS pathogenesis.
Sections du résumé
BACKGROUND AND OBJECTIVE
To explore the association between lipids, polygenic profile scores (PPS) for biomarkers of lipid metabolism, markers of disease severity, and survival in patients with amyotrophic lateral sclerosis (ALS).
METHODS
We meta-analyzed the current literature on the prognostic value of lipids in patients with ALS. Subsequently, we evaluated the relationship between lipid levels at diagnosis, clinical disease stage, and survival in all consecutive patients diagnosed in the Netherlands. We determined the hazard ratio (HR) of each lipid for overall survival, defined as death from any cause. A subset of patients was matched to a previous genome-wide association study; data were used to calculate PPS for biomarkers of lipid metabolism and to determine the association between observed lipid levels at diagnosis and survival.
RESULTS
Meta-analysis of 4 studies indicated that none of the biomarkers of the lipid metabolism were statistically significantly associated with overall survival; there was, however, considerable heterogeneity between study results. Using individual patient data (N = 1,324), we found that increased high-density lipoprotein (HDL) cholesterol was associated with poorer survival (HR of 1.33 (95% CI 1.14-1.55,
DISCUSSION
Lipids may contain valuable information about disease severity and prognosis, but their main value may be driven as a consequence of disease progression. Our results underscore that gaining further insight into lipid metabolism and longitudinal data on serum concentrations of the lipid profile could improve the monitoring of patients and potentially further disentangle ALS pathogenesis.
Identifiants
pubmed: 36460467
pii: WNL.0000000000201657
doi: 10.1212/WNL.0000000000201657
pmc: PMC9990853
doi:
Substances chimiques
Triglycerides
0
Cholesterol, HDL
0
Biomarkers
0
Types de publication
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1062-e1071Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
BMJ. 1989 Mar 25;298(6676):784-8
pubmed: 2496857
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):867-875
pubmed: 32576612
Neurology. 2008 Mar 25;70(13):1004-9
pubmed: 18199832
J Clin Lipidol. 2017 Jul - Aug;11(4):1055-1064.e6
pubmed: 28697983
Oxid Med Cell Longev. 2020 Nov 15;2020:5021694
pubmed: 33274002
Brain. 2012 Mar;135(Pt 3):751-64
pubmed: 22366792
Obes Rev. 2004 Feb;5(1):43-50
pubmed: 14969506
Neurology. 2009 Nov 17;73(20):1681-5
pubmed: 19917991
J Neurol. 2011 Apr;258(4):613-7
pubmed: 21128082
Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):359-65
pubmed: 26121273
Eur Heart J. 2016 Jul 01;37(25):1944-58
pubmed: 27122601
JAMA Psychiatry. 2021 Jan 1;78(1):101-109
pubmed: 32997097
Curr Med Chem. 2008;15(22):2265-70
pubmed: 18781948
Eur J Neurol. 2021 Nov;28(11):3615-3625
pubmed: 34216521
Neurology. 2006 Jan 24;66(2):265-7
pubmed: 16434671
Ann Neurol. 2002 Oct;52(4):448-57
pubmed: 12325074
Res Synth Methods. 2021 Jul;12(4):448-474
pubmed: 33486828
Lancet Neurol. 2014 Nov;13(11):1108-1113
pubmed: 25300936
Oxid Med Cell Longev. 2019 Jun 9;2019:1712323
pubmed: 31281567
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
J Neuropathol Exp Neurol. 2010 Jun;69(6):593-605
pubmed: 20467332
Stat Med. 2009 Jul 10;28(15):1982-98
pubmed: 19452569
Lancet. 2014 Jun 14;383(9934):2065-2072
pubmed: 24582471
PLoS Med. 2020 Mar 23;17(3):e1003062
pubmed: 32203549
J Alzheimers Dis. 2018;61(2):773-783
pubmed: 29254092
Curr Opin Neurol. 2021 Oct 1;34(5):773-780
pubmed: 34343139
Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):478-84
pubmed: 26161993
J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):638-42
pubmed: 21471184
Semin Cell Dev Biol. 2021 Apr;112:69-81
pubmed: 32962914
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):490-496
pubmed: 31347407
Nat Genet. 2021 Dec;53(12):1636-1648
pubmed: 34873335
Sci Rep. 2022 Feb 3;12(1):1826
pubmed: 35115598
Neurology. 2020 Apr 28;94(17):e1835-e1844
pubmed: 32221024
J Lipid Res. 2017 Jan;58(1):267-278
pubmed: 27811233
Brain. 2012 Mar;135(Pt 3):847-52
pubmed: 22271664
J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):75-81
pubmed: 34518331
Front Neurol. 2019 Apr 04;10:284
pubmed: 31019485
Circ Genom Precis Med. 2021 Feb;14(1):e003128
pubmed: 33433237
Stat Med. 1991 Apr;10(4):585-98
pubmed: 2057657
Am J Hum Genet. 2020 Sep 3;107(3):418-431
pubmed: 32758451
Lancet Neurol. 2018 May;17(5):423-433
pubmed: 29598923
Ann Intern Med. 2013 Feb 19;158(4):280-6
pubmed: 23420236
J Gen Intern Med. 2000 Jun;15(6):395-9
pubmed: 10886474
Neth Heart J. 2021 Sep;29(9):441-450
pubmed: 33844162
Ann Neurol. 2020 Feb;87(2):206-216
pubmed: 31849093
J Acad Nutr Diet. 2013 Dec;113(12):1640-61
pubmed: 24139973
Obes Surg. 2011 Jan;21(1):42-7
pubmed: 20563664